Compare · RVTY vs SEER
RVTY vs SEER
Side-by-side comparison of Revvity Inc. (RVTY) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.19B, about 113.7x SEER ($98.4M).
- Over the past year, RVTY is up 8.0% and SEER is down 18.4% - RVTY leads by 26.4 points.
- SEER has been more active in the news (17 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (19 ratings vs 8 for SEER).
- Company
- Revvity Inc.
- Seer Inc.
- Price
- $100.33+1.92%
- $1.80+0.84%
- Market cap
- $11.19B
- $98.4M
- 1M return
- +1.48%
- -4.51%
- 1Y return
- +8.03%
- -18.37%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 17
- Recent ratings
- 19
- 8
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)
Latest SEER
- SEC Form DFRN14A filed by Seer Inc.
- Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFC14A filed by Seer Inc.
- SEC Form DEFC14A filed by Seer Inc.
- Seer Files ITC Complaint Against Nanomics
- SEC Form DFAN14A filed by Seer Inc.
- The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
- Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026